"目錄號(hào): HY-14739

Cell Cycle/DNA DamageNF-κBMetabolic Enzyme/Protease-

Choline Fenofibrate (ABT-335)是fenofibric acid的膽堿鹽，可與rosuvastatin結(jié)合作用于血脂異常。

PPARCytochrome P450

相關(guān)產(chǎn)品

Talarozole-GW9662-Rosiglitazone-Retinoic acid-Abiraterone acetate-Troglitazone-Pioglitazone hydrochloride-Elafibranor-GW 501516-CDDO-Im-Cobicistat-Fenofibrate-FICZ-T0070907-Wy-14643-

生物活性

Description

Choline Fenofibrate (ABT-335) is the choline salt of fenofibric acid under clinical development as a combination therapy with rosuvastatin for the management of dyslipidemia. IC50 value:Target:Several clinical trials have been developed with Choline Fenofibrate on Reverse Cholesterol Transport, Macular Edema and Hypertriglyceridemia.

Clinical Trial

NCT00463606

AstraZeneca

Hypercholesterolemia-Dyslipidemia

April 2007

Phase 3

NCT00839293

Abbott

Healthy

February 2009

Phase 1

NCT00680017

AstraZeneca

Dyslipidemia-Kidney Disease

June 2008

Phase 3

NCT00585143

AstraZeneca

Dyslipidemia, Renal Insufficiency

January 2008

Phase 1

NCT00487136

AstraZeneca

Healthy

June 2007

Phase 1

NCT00616772

AbbVie (prior sponsor, Abbott)-AbbVie

Coronary Artery Disease-Coronary Heart Disease-Dyslipidemia

February 2008

Phase 3

NCT00300430

Abbott

Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia

September 2006

Phase 3

NCT00491530

Abbott

Mixed Dyslipidemia

June 2007

Phase 3

NCT00639158

Abbott

Dyslipidemias-Coronary Heart Disease-Combined (Atherogenic) Dyslipidemia-Mixed Dyslipidemia

February 2008

Phase 3

NCT00300456

Abbott

Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia

March 2006

Phase 3

NCT00681525

Abbott

Pharmacokinetics

April 2008

Phase 1

NCT00728780

AstraZeneca

Adverse Events-Pharmacokinetic Variables

August 2008

Phase 1

NCT00808678

AstraZeneca

Healthy

December 2008

Phase 1

NCT00826358

AstraZeneca

Healthy

November 2008

Phase 1

NCT00300469

Abbott

Mixed Dyslipidemia-Coronary Heart Disease-Dyslipidemia

March 2006

Phase 3

NCT00300482

Abbott

Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia

March 2006

Phase 3

NCT00681395

AstraZeneca

Adverse Events-Pharmacokinetic

May 2008

Phase 1

NCT00728910

University of Pennsylvania-Abbott

Dyslipidemia

June 2008

Phase 2

NCT00673881

Radiant Research

Dyslipidemia

March 2008

Phase 1-Phase 2

NCT00683176

Abbott Products-Abbott

Diabetic Macular Edema

September 2008

Phase 2

NCT00463606

AstraZeneca

Hypercholesterolemia-Dyslipidemia

April 2007

Phase 3

NCT00839293

Abbott

Healthy

February 2009

Phase 1

NCT00680017

AstraZeneca

Dyslipidemia-Kidney Disease

June 2008

Phase 3

NCT00585143

AstraZeneca

Dyslipidemia, Renal Insufficiency

January 2008

Phase 1

NCT00487136

AstraZeneca

Healthy

June 2007

Phase 1

NCT00616772

AbbVie (prior sponsor, Abbott)-AbbVie

Coronary Artery Disease-Coronary Heart Disease-Dyslipidemia

February 2008

Phase 3

NCT00300430

Abbott

Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia

September 2006

Phase 3

NCT00491530

Abbott

Mixed Dyslipidemia

June 2007

Phase 3

NCT00639158

Abbott

Dyslipidemias-Coronary Heart Disease-Combined (Atherogenic) Dyslipidemia-Mixed Dyslipidemia

February 2008

Phase 3

NCT00300456

Abbott

Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia

March 2006

Phase 3

NCT00681525

Abbott

Pharmacokinetics

April 2008

Phase 1

NCT00728780

AstraZeneca

Adverse Events-Pharmacokinetic Variables

August 2008

Phase 1

NCT00808678

AstraZeneca

Healthy

December 2008

Phase 1

NCT00826358

AstraZeneca

Healthy

November 2008

Phase 1

NCT00300469

Abbott

Mixed Dyslipidemia-Coronary Heart Disease-Dyslipidemia

March 2006

Phase 3

NCT00300482

Abbott

Dyslipidemia-Coronary Heart Disease-Mixed Dyslipidemia

March 2006

Phase 3

NCT00681395

AstraZeneca

Adverse Events-Pharmacokinetic

May 2008

Phase 1

NCT00728910

University of Pennsylvania-Abbott

Dyslipidemia

June 2008

Phase 2

NCT00673881

Radiant Research

Dyslipidemia

March 2008

Phase 1-Phase 2

NCT00683176

Abbott Products-Abbott

Diabetic Macular Edema

September 2008

Phase 2

View MoreCollapse

References

[1].Jones PH, Bays HE, Davidson MH et al. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme. Clin Drug Investig. 2008;28(10):625-34.

[2].Mohiuddin SM, Pepine CJ, Kelly MT et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J. 2009 Jan;157(1):195-203.

[3].Zhu T, Awni WM, Hosmane B et al. ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans. J Clin Pharmacol. 2009 Jan;49(1):63-71.

[4].Goldberg AC, Bays HE, Ballantyne CM et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009 Feb 15;103(4):515-22.

[5].Campbell J, Mohiuddin SM. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes. Drugs Today (Barc). 2010 Oct;46(10):757-64.